Thirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.

“Jazz continues to be committed to deepening our understanding of sleep disorders and delivering transformational medicines to those with lifelong and chronic sleep conditions,” says Robert Iannone, MD, MSCE, executive vice president, research and development and chief medical officer of Jazz Pharmaceuticals, in a release. “There remains a large unmet need for people living with sleep disorders, including narcolepsy and idiopathic hypersomnia, and we look forward to showcasing the latest research and results from our portfolio during SLEEP 2021 as we work to help people with sleep disorders live fuller lives.”

Highlights from Jazz at SLEEP 2021 will include the following presentations:

  • A late-breaking abstract poster presentation on June 13 on a sub-group analysis of Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution compared to placebo in adults with idiopathic hypersomnia with long sleep time (n=25) and without long sleep time (n=91), and the importance of treatment effects on those two groups
  • Additional data results from the Phase 3, placebo-controlled, double-blind, randomized withdrawal study of Xywav in adults with idiopathic hypersomnia including an oral presentation of the correlation of the idiopathic hypersomnia severity scale score with other measures of sleep parameters
  • Results from a real-world study of the cardiovascular burden of narcolepsy
  • Data results from the titration and administration (START) study of Sunosi (solriamfetol) in patients with narcolepsy

Xywav is not currently approved by regulatory authorities for the treatment of idiopathic hypersomnia.

Find a full list of Jazz-supported data below:

Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution Oral Presentation and Posters
Presentation TitleAuthorPresentation Date / Time
(EDT) & Number
Correlation of the Idiopathic Hypersomnia Severity Scale Score
With Other Measures of Sleep Parameters in a Phase 3 Trial
Dauvilliers et al.Oral PresentationSunday, June 13
12:41-12:52 PMAbstract ID: 500
Placebo-Controlled, Double-Blind, Randomized Withdrawal Study
of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia
Dauvilliers et al.ePoster PresentationAbstract ID: 494
Efficacy and Safety of Lower-Sodium Oxybate in Adults With
Idiopathic Hypersomnia: With and Without Long Sleep Time
Bogan et al.ePoster PresentationAbstract ID: LBA070
Effect of Lower-Sodium Oxybate on Sleep Inertia in Idiopathic 
Hypersomnia in a Double-Blind, Randomized Withdrawal Study
Bogan et al.ePoster PresentationAbstract ID: 487
Efficacy and Safety of Once- and Twice-Nightly Dosing of
Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia
Arnulf et al.ePoster PresentationAbstract ID: 485
Efficacy of Lower-Sodium Oxybate on Idiopathic Hypersomnia, Measured
by the Idiopathic Hypersomnia Severity Scale
Foldvary-Schaefer et al.ePoster PresentationAbstract ID: 495
Clinical Presentation Prior to Idiopathic Hypersomnia Diagnosis Among
US Adults: A Retrospective, Real-World Claims Analysis
Saad et al.ePoster PresentationAbstract ID: 497
Utilization of Diagnostic Sleep Testing Prior to Idiopathic Hypersomnia
Diagnosis Among US Adults: A Real-World Claims Analysis
Saad et al.ePoster PresentationAbstract ID: 499
Timing and Duration of Adverse Events in a Clinical Trial of Lower-Sodium 
Oxybate in Participants With Narcolepsy With Cataplexy
Bogan et al.ePoster PresentationAbstract ID: 486
Cardio-Vascular Burden of Narcolepsy Disease (CV-BOND): A Real-World
Evidence Study
Ben-Joseph et al.ePoster PresentationAbstract ID: 503
Sunosi® (solriamfetol) Poster Presentations
Presentation TitleAuthorPresentation Number
Solriamfetol Titration & Administration (START): Characteristics of Patients
With Narcolepsy and Solriamfetol Prescriber Rationale
Thorpy et al.ePoster PresentationAbstract ID: 481
Solriamfetol Titration & Administration (START): Dosing and Titration Strategies
in Patients With Narcolepsy Starting Solriamfetol
Thorpy et al.ePoster PresentationAbstract ID: 482
Solriamfetol Titration & Administration (START): Physician Titration Strategies 
in a Hypothetical Patient With Narcolepsy
Singh et al.ePoster PresentationAbstract ID: 484
Additionally, data from the following investigator-sponsored trials will be presented as poster presentations:
Presentation TitleAuthorPresentation Number
Impact of A Single Sleep Education Session on Beliefs and Attitudes Among People
with Excessive Daytime Sleepiness: A Pilot Study
Grandner et al.ePoster PresentationAbstract ID: 089
Strategies for Dealing with or Ameliorating Excessive Sleepiness: Beliefs and
Attitudes of People with Daytime Sleepiness
Grandner et al.ePoster PresentationAbstract ID: 090
Seeking Treatment for Daytime Sleepiness: Beliefs and Attitudes Among People
with Excessive Daytime Sleepiness
Grandner et al.ePoster PresentationAbstract ID: 120
It Makes Relationships Harder: The Role of Narcolepsy in Social and Romantic
Relationships in Young Adults
Zhou et al.ePoster PresentationAbstract ID: 498
The Effect of Sodium Oxybate on Cataplexy in Orexin -/- MiceHamieh et alePoster PresentationAbstract ID: 006